Targets › IL-18R1
1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Nov 2026.
Open in Phaseline: the race on IL-18R1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Tulisokibart (MK-7240/PRA023) IL-18 receptor antagonist | IL-18R1 | Phase 2 | Diffuse Cutaneous Systemic Sclerosis | Nov 2026 |
Diffuse Cutaneous Systemic Sclerosis (1)
antibody (1)
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.